CO2022014134A2 - N-cianopirrolidinas con actividad como inhibidores de usp30 - Google Patents
N-cianopirrolidinas con actividad como inhibidores de usp30Info
- Publication number
- CO2022014134A2 CO2022014134A2 CONC2022/0014134A CO2022014134A CO2022014134A2 CO 2022014134 A2 CO2022014134 A2 CO 2022014134A2 CO 2022014134 A CO2022014134 A CO 2022014134A CO 2022014134 A2 CO2022014134 A2 CO 2022014134A2
- Authority
- CO
- Colombia
- Prior art keywords
- cyanopyrrolidines
- activity
- usp30
- inhibitors
- usp30 inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se relaciona con una clase de N-cianopirrolidinas con actividad como inhibidores de la enzima desubiquitilante USP30, que tiene utilidad en una variedad de áreas terapéuticas, incluyendo condiciones que involucran disfunción mitocondrial, cáncer y fibrosis:
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2005250.2A GB202005250D0 (en) | 2020-04-08 | 2020-04-08 | Novel compounds |
GBGB2016607.0A GB202016607D0 (en) | 2020-10-20 | 2020-10-20 | Novel Compounds |
PCT/EP2021/059032 WO2021204856A1 (en) | 2020-04-08 | 2021-04-07 | N-cyanopyrrolidines with activity as usp30 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2022014134A2 true CO2022014134A2 (es) | 2022-10-31 |
Family
ID=75441909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2022/0014134A CO2022014134A2 (es) | 2020-04-08 | 2022-09-30 | N-cianopirrolidinas con actividad como inhibidores de usp30 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230119013A1 (es) |
EP (1) | EP4132925A1 (es) |
JP (1) | JP2023520727A (es) |
KR (1) | KR20230006487A (es) |
CN (1) | CN115461340A (es) |
AU (1) | AU2021253617A1 (es) |
BR (1) | BR112022020058A2 (es) |
CA (1) | CA3171349A1 (es) |
CO (1) | CO2022014134A2 (es) |
IL (1) | IL296998A (es) |
MX (1) | MX2022012578A (es) |
WO (1) | WO2021204856A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB202016800D0 (en) | 2020-10-22 | 2020-12-09 | Mission Therapeutics Ltd | Novel compounds |
WO2023099561A1 (en) | 2021-12-01 | 2023-06-08 | Mission Therapeutics Limited | Substituted n-cyanopyrrolidines with activity as usp30 inhibitors |
CN117887844A (zh) * | 2023-12-28 | 2024-04-16 | 中山大学附属第一医院 | Usp20在肝癌放疗增敏中的应用 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
US6835727B2 (en) | 2000-04-06 | 2004-12-28 | Merck Frosst Canada & Co. | Cathepsin cysteine protease inhibitors |
PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
KR20080111137A (ko) | 2006-04-13 | 2008-12-22 | 액테리온 파마슈티칼 리미티드 | 초기 단계 특발성 폐 섬유증을 위한 엔도텔린 수용체 대항제 |
CA2689989A1 (en) | 2007-06-04 | 2008-12-11 | Avila Therapeutics, Inc. | Heterocyclic compounds and uses thereof |
CL2008002430A1 (es) | 2007-08-20 | 2009-10-16 | Glaxo Group Ltd | Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc. |
UY31771A1 (es) | 2008-04-18 | 2009-09-30 | Inhibidores de catepsina c | |
WO2009129370A1 (en) | 2008-04-18 | 2009-10-22 | Glaxo Group Limited | Cathepsin c inhibitors |
CL2009000915A1 (es) | 2008-04-18 | 2010-04-16 | Glaxo Group Ltd | Compuestos derivados de 1-ciano-3-pirrolidinil-bencenosulfonamidas, inhibidores de catepsina c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad pulmonar obstructiva cronica (copd). |
US20120309820A1 (en) | 2011-06-04 | 2012-12-06 | Jb Therapeutics Inc. | Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids |
EP2565186A1 (en) | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
LT3049417T (lt) | 2013-07-31 | 2019-02-11 | Merck Patent Gmbh | Piridinai, pirimidnai ir pirazinai kaip btk inhibitoriai ir jų panaudojimas |
WO2015179190A1 (en) | 2014-05-19 | 2015-11-26 | Northeastern University | N-acylethanolamine hydrolyzing acid amidase (naaa) inhibitors and their use thereof |
JP2017516801A (ja) | 2014-05-27 | 2017-06-22 | ファーマケア,インク. | 脱ユビキチン化酵素阻害剤の組成物と送達の方法 |
WO2016019237A2 (en) | 2014-07-31 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
DK3277677T3 (da) | 2015-03-30 | 2021-05-25 | Mission Therapeutics Ltd | 1-cyano-pyrrolidinforbindelser som usp30-hæmmere |
EP3800186A1 (en) | 2015-07-14 | 2021-04-07 | Mission Therapeutics Limited | Cyanopyrrolidines as dub inhibitors for the treatment of cancer |
GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
EP3433246B1 (en) | 2016-03-24 | 2022-05-04 | Mission Therapeutics Limited | 1-cyano-pyrrolidine derivatives as dbu inhibitors |
EP3519385B1 (en) | 2016-09-27 | 2020-11-18 | Mission Therapeutics Limited | Cyanopyrrolidine derivatives with activity as inhibitors of usp30 |
GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
US10968172B2 (en) | 2017-05-15 | 2021-04-06 | Mitobridge, Inc. | USP30 inhibitors |
GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
GB2563595B (en) | 2017-06-19 | 2020-04-15 | Edwards Ltd | Twin-shaft pumps |
EA202090871A1 (ru) | 2017-10-06 | 2020-07-03 | Форма Терапьютикс, Инк. | Ингибирование убиквитин-специфической пептидазы 30 |
GB2571731A (en) | 2018-03-06 | 2019-09-11 | Mission Therapeutics Ltd | Novel compounds and uses |
CA3098628A1 (en) | 2018-05-17 | 2019-11-21 | Forma Therapeutics, Inc. | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors |
US11572374B2 (en) | 2018-08-14 | 2023-02-07 | Amgen Inc. | N-cyano-7-azanorbornane derivatives and uses thereof |
MX2021002981A (es) | 2018-10-05 | 2021-05-14 | Forma Therapeutics Inc | Pirrolinas fusionadas que actuan como inhibidores de la proteasa 30 especifica de la ubiquitina (usp30). |
GB201905371D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
GB201905375D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
GB201912674D0 (en) | 2019-09-04 | 2019-10-16 | Mission Therapeutics Ltd | Novel compounds |
-
2021
- 2021-04-07 WO PCT/EP2021/059032 patent/WO2021204856A1/en unknown
- 2021-04-07 EP EP21717825.0A patent/EP4132925A1/en active Pending
- 2021-04-07 IL IL296998A patent/IL296998A/en unknown
- 2021-04-07 MX MX2022012578A patent/MX2022012578A/es unknown
- 2021-04-07 JP JP2022561565A patent/JP2023520727A/ja active Pending
- 2021-04-07 CN CN202180023434.1A patent/CN115461340A/zh active Pending
- 2021-04-07 BR BR112022020058A patent/BR112022020058A2/pt unknown
- 2021-04-07 AU AU2021253617A patent/AU2021253617A1/en active Pending
- 2021-04-07 KR KR1020227038744A patent/KR20230006487A/ko active Search and Examination
- 2021-04-07 CA CA3171349A patent/CA3171349A1/en active Pending
- 2021-04-07 US US17/914,414 patent/US20230119013A1/en active Pending
-
2022
- 2022-09-30 CO CONC2022/0014134A patent/CO2022014134A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2021253617A1 (en) | 2022-12-01 |
IL296998A (en) | 2022-12-01 |
WO2021204856A1 (en) | 2021-10-14 |
BR112022020058A2 (pt) | 2022-11-22 |
EP4132925A1 (en) | 2023-02-15 |
CN115461340A (zh) | 2022-12-09 |
CA3171349A1 (en) | 2021-10-14 |
MX2022012578A (es) | 2022-11-07 |
KR20230006487A (ko) | 2023-01-10 |
US20230119013A1 (en) | 2023-04-20 |
JP2023520727A (ja) | 2023-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2022003608A2 (es) | Cianopirrolidinas sustituidas con actividad como inhibidores de usp30 | |
CO2022014134A2 (es) | N-cianopirrolidinas con actividad como inhibidores de usp30 | |
ECSP17055491A (es) | Ácidos 3-alquil-4-amido-bicíclico [4,5,0] hidroxámico como inhibidores de hdac | |
CR20170014A (es) | Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer | |
AU201712054S (en) | A Mask | |
MX2016006489A (es) | Alfa-amilasas variantes que tienen susceptibilidad reducida a la escision por proteasas y metodos de uso. | |
CR20140586A (es) | Celulas para producir iduronato-2-sulfatasa recombinante | |
CO2022017233A2 (es) | 1-(5-(2-cianopiridin-4-il)oxazol-2-carbonil)-4-metilhexahidropirrolo[3,4-b]pirrol-5(1h)-carbonitrilo como inhibidor de usp30 para uso en el tratamiento de la disfunción mitocondrial, cáncer y fibrosis | |
MX2016000794A (es) | Composiciones farmaceuticas de pancreatina de potencia alta. | |
CO7131352A2 (es) | Composiciones farmacéuticas tópicas | |
UY4759S (es) | Modelo industrial de cuerpo de extintor de incendios | |
MX2023002411A (es) | Celulas inmunitarias modificadas para fibrosis e inflamacion. | |
MX2016000480A (es) | Composiciones farmaceuticas de pancreatina de alta potencia. | |
CO2022017112A2 (es) | N-cianopirrolidinas con actividad como inhibidores de peptidasa específica de ubiquitina 30 | |
CO2022014135A2 (es) | Derivados de n-(1-ciano-pirrolidin-3-il)-5-(3-(trifluorometil)fenil)oxazol-2-carboxamida y los derivados oxadiazol correspondientes como inhibidores de usp30 para el tratamiento de disfunción mitocondrial | |
UY37534A (es) | Metodo para el tratamiento de enfermedades fibroticas utilizando el interferon-lambda | |
AU201814479S (en) | A toothbrush | |
CL2019000429A1 (es) | Conjugado de minoxidil y peptidos. | |
BR112014021326A2 (pt) | célula para a expressão de protéina, método para reduzir a atividade de amidação de peptídeo em uma determinada célula, uso de uma célula | |
UY35695A (es) | Composicion para el tratamiento contra el envejecimiento de la piel | |
PE20121537A1 (es) | Combinacion de teobromina con un descongestivo | |
PL409283A1 (pl) | Enzym o wysokiej aktywności litycznej w stosunku do komórek Enterococcus oraz sposób modyfikacji jego genu pozwalający na nadprodukcję aktywnego enzymu w komórkach bakteryjnych | |
CO6720990A2 (es) | Una nueva variante del factor viii antihemofílico con actividad específica aumentada | |
MX2017008365A (es) | Composicion fertilizante a base de hidrolizados de soya. | |
CR20160116A (es) | Método para tratar onicomicosis con hidroxipropil quitasano |